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That biotechnology hasbrought changes to agricul-ture in a very short time is, by
now, obvious. For the 2004 harvest,
for example, it is estimated that 85
percent of U.S. soybean production
and 45 percent of U.S. corn produc-
tion will come from genetically modi-
fied (GM) varieties (89 percent and 54
percent, respectively, in Iowa). While
the agricultural sector is still dealing
with problematic trade effects
caused by less-than-enthusiastic con-
sumer acceptance and restrictive
regulations overseas, the biotech in-
dustry is actively pursuing an array of
R&D efforts that could make the cur-
rent adoption of GM crops just the
prototypical “tip of the iceberg.”
At the risk of oversimplifying,
we can distinguish three distinct
waves of innovation. The first gen-
eration of GM crops has served the
interests of the farm sector, modify-
ing genetic inputs to manage agro-
nomic problems such as weeds and
insects. The second generation of
GM crops seeks to address the inter-
ests of end users, by improving nu-
tritional and quality characteristics
of food, feed, and fiber. The third
wave aims to “biomanufacture”
pharmaceuticals, vaccines, and in-
dustrial compounds in traditional
crops. Needless to say, the prospect
of crops intended to deliver plant-
made pharmaceuticals (PMPs) and
plant-made industrial products
(PMIPs) has attracted considerable
attention, both for its exciting sci-
entific and technological prospects
and for the implications it may have
for the agricultural sector.
THE POTENTIAL SCOPE OF
BIOMANUFACTURING
To be clear agriculture has long
served to “biomanufacture” a wide
array of biomaterials, including com-
pounds used in drugs, stimulants,
dietary supplements, flavorings, fill-
ers, lubricants, dyes, adhesives, fuels,
and more. Yet, these products are
either singularly derived from a spe-
cifically cultivated natural source
(for example, coffee and natural rub-
ber) or they are essentially by-prod-
ucts from major food crops (for
example, lubricants derived from
soybean oil). In contrast, with mod-
ern biomanufacturing, common crop
species can be genetically engi-
neered to synthesize and deliver a
broad range of unique biomolecules
needed for medical or industrial use.
In theory, production of almost any
kind of biomolecule could be engi-
neered into plant hosts—including
nucleic acids, carbohydrates, oils,
and secondary metabolites such as
vitamins. However, today most R&D
is focused on expressing just a hand-
ful of valuable proteins, mostly anti-
bodies, vaccines, enzymes, and other
pharmaceutical proteins.
Some indication of the number
of genetically engineered biomanu-
facturing crops moving toward com-
mercialization can be gleaned from
data on field-trial permits issued by
the USDA. These have increased
steadily since the first permit (for
production of the enzyme amylase)
was granted in 1991 (see Figure 1). A
high point was reached in 2000,
when over 40 permits were sought.
The number of field trials took a big
dip in 2002 and 2003, because of in-
dustry-wide biosafety concerns fol-
lowing the ProdiGene fiasco (more
on this to follow). Fieldwork seems
to be picking up again in 2004. At
present, we estimate that over 25 per-
mits will be granted this year.
Crop biomanufacturing is attrac-
tive because of the potentially large
cost savings that could result from
using high-yielding and easily culti-
vated crops. Compared with current
fermentation biomanufacturing tech-
niques, crops would have a compara-
tive advantage in both the absolute
scale of production and the rate of
scalability that could be achieved,
resulting in lower cost, faster speed
to market, and considerably smaller
up-front fixed investments. Other
benefits would include purity of the
resulting product (with no animal
pathogens or cell culture contami-
nants), ease of storage and transport,
and convenience of oral delivery of
the product.
THE COSTS OF RISK AND
REGULATION
A major issue with crop biomanu-
facturing is the potentially large risks
that may be involved. The essence of
the problem is the reliance on crops
that until now have been used exclu-
sively for food or feed to produce
bioactive compounds which may, un-
der certain conditions, turn out to be
toxins, allergens, or to have hormonal
effects. Although grown and handled
separately, the possibility arises that
these compounds, intended for phar-
maceutical or industrial use, could end
up in food and feed supplies by acci-
dent. There is thus a real, objective risk
of direct harm to human health and
the environment.
Risk specialist Robert Peterson
and plant biologist Charles Arntzen, in
the February 2004 issue of Trends in
Biotechnology, argue that, while some of
these proteins may be quite novel, few
are likely to be highly harmful, and any
direct food safety risk they pose is
both identifiable and manageable. In
short, actual harm is highly unlikely.
Yet, the indirect risk from such an
eventuality could be catastrophic from
an economic point of view. An incident
could call into question the very integ-
rity of the food supply. The food indus-
try is particularly concerned, and both
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the National Food Processors Associa-
tion and the Grocery Manufacturers of
America have taken strong positions in
favor of strict regulation to achieve
maximum protection of the food sup-
ply (and their members’ brand name
products) from possible contamina-
tion by PMPs and PMIPs. Indeed, the
biotech industry should be extremely
concerned as well, as any possible real-
ization of undesirable, unintended ef-
fects would be seized upon by an
already active anti-biotech lobby and
could prove crippling for future bio-
technology research.
U.S. regulation in this area is under-
going an extensive (and unfinished)
review. Current and interim rules, how-
ever, implicitly presume a zero toler-
ance level for the presence of PMPs
and PMIPs in the food supply. Such a
strict requirement may be impossible
to achieve in practice and may indeed
impose unnecessary costs without in-
creasing safety. Given that some of the
proteins are known to pose little or no
risk, whereas others pose indetermi-
nate or high risk, it would seem sen-
sible to regulate them differently.
Regulations that impose zero-tolerance
across the board may result in unnec-
essary precautions for low-risk prod-
ucts while diluting the resources and
attention spent on the actual high
risks. Yet, the overriding objective of
preserving public confidence in the
integrity of the food supply may re-
quire a stricter, and seemingly less effi-
cient, regulation.
The ProdiGene incident illus-
trates the potential dangers. In 2002,
the USDA found that volunteer corn
that was genetically engineered by
ProdiGene (a small, privately held
biotech company and a leading firm in
this technology) to express a vaccine
for a viral disease in pigs had contami-
nated some soybean fields in Ne-
braska and Iowa. These volunteer
plants were left over from field tests
carried out (under duly obtained
USDA permits) the year before. De-
spite lack of evidence that such a con-
tamination posed any health risk, the
product from these soybean fields
(500,000 bushels) was quarantined
and eventually destroyed. ProdiGene
paid a fine of $250,000 and had to bear
the cost of destroying the contami-
nated product ($3 million). The ensu-
ing financial stress on the company
resulted in it being sold to a third
party, Stine Seed, in 2003.
To avoid contamination of food
and feed by PMPs and PMIPs, a failsafe
containment and segregation program
must be put in place. That will neces-
sarily entail use of physical separation
between pharmaceutical or industrial
crops and conventional feed and food
crops. One low-cost spatial segrega-
tion solution would be not to grow
PMP corn in the Corn Belt. The other
logical measure often suggested is sim-
ply to use plants other than food and
feed crops to produce PMP and
PMIPs—tobacco, for example, or even
duckweed. It is true that, both at the
research stage and at the production
stage, it is comparatively easier to use
corn as the vector for pharmaceutical
and industrial traits than to use, say,
duckweed. But such an efficiency ad-
vantage may pale in comparison with
the potential costs that would arise if
high-risk pharmaceutical proteins
were to end up in the food chain.
MARKET IMPACTS AND THE
AGRICULTURAL SECTOR
Demand for biomanufacturing of re-
combinant proteins is rapidly growing,
in both breadth (with more and more
new proteins introduced) and depth
(with greater volumes demanded of
existing proteins). Over one-third of the
new drugs approved since 2000 have
been therapeutic proteins, with the
proportion expected to increase in
coming years. Datamonitor estimates
annual global sales of therapeutic pro-
teins in final pharmaceutical markets at
$30 billion and growing at 20 percent
per year, with sales approaching $60
billion by 2010. Antibodies represent
the most promising therapeutic market
for crop biomanufacturing, as demand
is growing particularly fast, and signifi-
cantly higher quantities are needed.
The market for industrial enzymes will
be an additional source of demand for
biomanufacturing, although it is con-
siderably smaller, at about $2 billion
and growing at about 5 percent.
Whether crop biomanufacturing
systems can significantly tap this
emerging market remains to be seen, as
there is significant competition from
other sources of biomanufacturing ca-
pacity. Today, virtually all recombinant
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FIGURE 1. NUMBER OF U.S. FIELD TRIAL PERMITS FOR GENETICALLY MODIFIED
CROPS FOR PLANT-MADE PHARMACEUTICALS AND PLANT-MADE INDUSTRIAL PRODUCTS
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proteins are produced by bacteria,
yeast, or mammalian cell lines in
closed-vessel fermentation facilities.
While they are costly up front, can
take several years to build and bring
online, and have limited capacity,
these methods enjoy the advantage of
being familiar to the pharmaceutical
industry and they are constantly being
improved by new R&D and learning-by-
doing. Furthermore, crops are not the
only “alternative” platform attempting
to enter the market. Biomanufacturing
based on other host organisms, includ-
ing transgenic livestock, algae, and
even insect larvae, are being rapidly
researched and developed.
Agriculture’s direct contribution
to this emerging industry, however,
may be limited. While PMPs or PMIPs
are highly valued, they often require
only a small amount of land to satisfy
demand. A recent report by bio-era (a
research firm in Cambridge, MA) con-
cludes that, in the next 10 years, an
optimistic scenario would be perhaps
25,000 acres, worldwide, devoted to
crop biomanufacturing. Even under
this rosy scenario, it is apparent that
biomanufacturing is not likely to affect
many large-scale farming operations.
Furthermore, in an effort to com-
ply with the expected stringent regula-
tion, companies developing these
crops are likely to maintain a tight con-
trol on the entire production cycle of
the products, acquiring land or farm
services under contract. And the im-
plicit costs of regulation may induce
crop biomanufacturing to locate away
from the traditional areas of agricul-
tural production, possibly outsourcing
overseas. That is, it is precisely because
they have a strong comparative advan-
tage in food and feed production that
locations such as Iowa may have a com-
petitive disadvantage in growing PMPs
and PMIPs. Ultimately, the returns to
agriculture will be for use of the land
and for services provided in the grow-
ing of the crop, a relatively small contri-
bution to the long process of produ-
cing and delivering PMPs and PMIPs to
end users.
PROSPECTS AND LIMITATIONS
Whereas the prospects of developing
crops genetically engineered to pro-
duce pharmaceuticals and industrial
products is exciting, there are four ma-
jor factors that may limit the potential
of crop biomanufacturing in the near
future. First, both scientifically based
risks and perceived risks to the food
supply and the environment will drive
up costs of regulatory compliance and
containment. Considerable fixed-cost
investments in land, equipment, and
professional expertise will be required
to enter the business. Also, the
technology’s owners will likely main-
tain an effective control on the produc-
tion of such crops in a tightly vertically
integrated structure to ensure highly
contained growing operations.
Second, the scale of production—
while potentially large from the per-
spective of the biotech industry—is
likely to remain quite small by agricul-
ture’s standards. Third, competition
from other biomanufacturing platforms
will continue to be fierce, as innovation
and development of capacity proceeds
on all fronts at a rapid pace. Contain-
ment risks will always remain much less
of an issue for in-vessel fermentation
systems than for agriculture, particu-
larly when food crops are involved.
Fourth, competition and industrial
structure within the crop biomanu-
facturing sector may keep margins low.
Contract structure for the farm-level
production stage will likely entail lim-
ited opportunities for primary contract
growers to capture the value.
It is of course possible that newer
biomanufacturing crops or technolo-
gies may prove to be exceptions to any
of these four factors. For example, high-
volume, high-acreage products, such as
specialized bio-energy feedstocks or
“functional” nutritional ingredients,
that require little or no segregation
from the food supply may emerge. With
such products, of course, major agricul-
tural producing regions will soon com-
pete globally, just as they do in com-
modity markets today. ◆
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